With China CNS Plans, SK Biopharm Completes Strategy For Key Markets

Raises $180M, Largest Series A In China Pharma Industry In 2021

SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.

SK Biopharm Sets Up New Pharma In China — SK Biopharm Licenses Out 6 CNS Pipelines To Newly Established Ignis • Source: SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd has unveiled plans to enter the Chinese market, the last of the four major global markets, including the US, Europe and Japan, it is targeting to advance into. The company has now set up a central nervous system focused Chinese company, Ignis Therapeutics, with the Shanghai-based global investment firm 6 Dimensions Capital.

“The launch of Ignis Therapeutics in China reaffirms our commitment to addressing unmet needs in CNS disorders, and bringing care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.